Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder
← Find more feeds

investor.incyte.com

Incyte Press Releases

Get the latest updates from Incyte Press Releases directly as they happen.

Follow now 63 followers

Latest posts

Last updated over 3 years ago

Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer

over 3 years ago

Incyte to Report First Quarter Financial Results

over 3 years ago

Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies

over 3 years ago

Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo

over 3 years ago

Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease

over 3 years ago

Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting

over 3 years ago

Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of Vitiligo

over 3 years ago

Incyte to Present at Upcoming Investor Conference

over 3 years ago

Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs

over 3 years ago

Incyte to Present at Upcoming Investor Conference

over 3 years ago

Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis

over 3 years ago

Incyte Provides Update on Parsaclisib and MCLA-145

over 3 years ago

Sign up to continue

Try Feeder for free

Everything you care about in one place

Try Feeder now